Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174181 | 0.83 | HTT (0.54) | ADORA1MAPTTHRBPOLBRXFP1 | |
| SCHEMBL2452454 | 0.81 | ALDH1A1 (0.46) | ADORA1MAPTPOLBSMN1; SMN2HTT | |
| SCHEMBL1599367 | 0.80 | ADORA1 (0.47) | ADORA1MAPTTHRBRPS6KB1AKT1 | |
| SCHEMBL15584189 | 0.80 | KDM4E (0.44) | ADORA1MAPTTHRBKDM4EALDH1A1 | |
| SCHEMBL22208165 | 0.79 | NPSR1 (0.62) | ADORA1MAPTTHRBPOLBSMN1; SMN2 | |
| SCHEMBL30065035 | 0.79 | NPSR1 (0.62) | ADORA1MAPTTHRBPOLBSMN1; SMN2 | |
| SCHEMBL15358450 | 0.79 | ADORA1 (0.51) | ADORA1MAPTTHRBPOLBSMN1; SMN2 | |
| SCHEMBL31141599 | 0.78 | HDAC3 (0.50) | ADORA1MAPTRPS6KB1AKT1POLB | |
| SCHEMBL4277553 | 0.77 | ALDH1A1 (0.45) | MAPTPOLBKDM4EALDH1A1GAA | |
| SCHEMBL16873158 | 0.77 | KDM4E (0.43) | MAPTKDM4EALDH1A1GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919511-B2 | Aminopyridines, e.g., 6-(2-cyanophenyl)-4-{[2-(3-fluorophenyl)ethyl]amino}(3-pyridyl))-N-(3-pyridylmethyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919511-B2 | Aminopyridines, e.g., 6-(2-cyanophenyl)-4-{[2-(3-fluorophenyl)ethyl]amino}(3-pyridyl))-N-(3-pyridylmethyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919511-B2 | Aminopyridines, e.g., 6-(2-cyanophenyl)-4-{[2-(3-fluorophenyl)ethyl]amino}(3-pyridyl))-N-(3-pyridylmethyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080146619-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146619-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146619-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146619-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ADORA1 2532/4885MAPT 540/4885THRB 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.